Skip to content

Performance Study of Nova StatStrip® Blood Glucose Monitoring Test System on Neonatal Capillary Blood

Performance Study of Nova StatStrip® Blood Glucose Monitoring Test System on Neonatal Capillary Blood

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04194476
Enrollment
120
Registered
2019-12-11
Start date
2025-01-01
Completion date
2025-03-30
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy and Unhealthy Neonates

Keywords

neonates, glucose

Brief summary

This study is to determine the validity of Nova StatStrip® blood glucose monitoring test system including the Nova StatStrip® glucose hospital meter and test strips in measuring Chinese neonatal capillary blood glucose levels by evaluating how the results compare to those obtained from laboratory hexokinase method. The study results will be the basis for the regulatory submission and registration of the Nova StatStrip® glucose hospital meter and test strips in testing the neonatal capillary whole blood specimens to the China Food and Drug Administration (CFDA). Good clinical practice indicates that the performance of a point-of-care glucose monitoring test system be validated before clinical use. It is therefore important to perform a method comparison study to determine how the results obtained from a type of glucose monitoring test system compare to those from a laboratory hexokinase method.

Interventions

DIAGNOSTIC_TESTStatStrip blood glucose meter and strips

We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.

Sponsors

Nova Biomedical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Days to 28 Days
Healthy volunteers
Yes

Inclusion criteria

* Subject is within 28 days after birth. * The legal representative of the Subject agrees to sign two copies of the Informed Consent Form. * The Subject's capillary whole blood needs to be drawn via heel stick for routine clinical laboratory testing according to the prescription. * The legal representative of the Subject agrees that the Subject provides 300 µL capillary whole blood for glucose and haematocrit testing in addition to routine clinical laboratory testing.

Exclusion criteria

* Subject/legal representative is currently working for, has previously worked for, or has an immediate family member working for a company manufacturing and/or marketing blood glucose monitoring products; * Subject has already participated in this study.

Design outcomes

Primary

MeasureTime frame
blood glucose level measured by StatStrip blood glucose meter6 months
plasma glucose level measured by a laboratory biochemistry analyzer6 months

Secondary

MeasureTime frame
hematocrit of the heel-stick blood6 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026